HP
LRMR icon

Harbourvest Partners’s Larimar Therapeutics LRMR Stock Holding History

Harbourvest Partners’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-9,325
Closed -$670K – 15
2016
Q2 		$670K Hold
9,325
– – 0.32% 13
2016
Q1 		$747K Hold
9,325
– – 0.32% 14
2015
Q4 		$704K Hold
9,325
– – 0.26% 16
2015
Q3 		$3.58M Buy
9,325
+2,872
+45% +$1.29M 1.58% 7
2015
Q2 		$2.68M Sell
6,453
-1,975
-23% -$826K 1.23% 6
2015
Q1 		$4.01M Buy
+8,428
New +$4M 2.27% 4

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Harbourvest Partners's LRMR Position: Q3 2016 in Review

Harbourvest Partners sold out of Larimar Therapeutics (LRMR) in Q3 2016, closing a stake of 9,325 shares — an estimated $670K sold.

Harbourvest Partners first reported a position in LRMR in Q1 2015 and held it in 6 quarters. The position peaked at $4.01M in Q1 2015. 77 funds tracked by Wall St. Rank hold LRMR as of Q3 2016.

  • Harbourvest Partners reported no remaining Larimar Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Harbourvest Partners sold 9,325 Larimar Therapeutics shares in Q3 2016, an estimated $670K.
  • Harbourvest Partners first reported a position in Larimar Therapeutics in Q1 2015 and held it in 6 quarters.
  • Harbourvest Partners's Larimar Therapeutics position peaked at $4.01M in Q1 2015.
  • 77 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2016.

Based on Harbourvest Partners's 13F filing for Q3 2016, filed 14 Nov 2016.